<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.34655.009</object-id><label>Table 1.</label><caption><title>Characteristics of HIV-1-infected study participants</title><p>ABC, abacavir; DRV, darunavir; FTC, emtricitabine; RPV, rilpivirine; RTV, ritonavir; TCV, tivicay; TDF, tenofovir; 3TC, lamivudine; VL, viral load.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Scope ID</th><th>Age</th><th>Sex</th><th>Ethnicity</th><th>CD4 <break/>Count</th><th>Duration of infection (years)</th><th>ART regimen</th><th>Duration of ART (years)</th><th>Peak reporter VL (copies/ml<sup>&#8722;1</sup>)</th></tr></thead><tbody><tr><td>&#8195;1597</td><td>56</td><td>M</td><td>Mixed</td><td>469</td><td>19</td><td>RPV/TDF/FTC</td><td>5</td><td>45734</td></tr><tr><td>&#8195;2147</td><td>59</td><td>M</td><td>Asian</td><td>597</td><td>28</td><td>RPV/TDF/FTC</td><td>23</td><td>374000</td></tr><tr><td>&#8195;2461</td><td>62</td><td>M</td><td>White</td><td>664</td><td>32</td><td>RPV/TCV</td><td>19</td><td>20000</td></tr><tr><td>&#8195;3162</td><td>54</td><td>M</td><td>White</td><td>734</td><td>29</td><td>RTV, DRV, ABC/TCV/3TC</td><td>20</td><td>171000</td></tr></tbody></table></table-wrap>